These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2905651)

  • 21. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tardive dyskinesia and essential fatty acids.
    Vaddadi K; Hakansson K; Clifford J; Waddington J
    Int Rev Psychiatry; 2006 Apr; 18(2):133-43. PubMed ID: 16777667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tardive dyskinesias].
    Mignot G
    Encephale; 1983; 9(2):151-66. PubMed ID: 6139271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can the supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia?
    Wolfarth S; Ossowska K
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):799-840. PubMed ID: 2682786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tardive dyskinesia: a review and current treatment options.
    Najib J
    Am J Ther; 1999 Jan; 6(1):51-60. PubMed ID: 10423647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.
    Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC
    Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Soares KV; McGrath JJ; Deeks JJ
    Cochrane Database Syst Rev; 2000; (2):CD000203. PubMed ID: 10796320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism.
    Wirshing WC; Freidenberg DL; Cummings JL; Bartzokis G
    J Clin Psychopharmacol; 1989 Dec; 9(6):407-11. PubMed ID: 2574192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulpiride in tardive dyskinesia.
    Gerlach J; Casey DE
    Acta Psychiatr Scand Suppl; 1984; 311():93-102. PubMed ID: 6142590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tardive dyskinesia.
    Soares-Weiser K; Fernandez HH
    Semin Neurol; 2007 Apr; 27(2):159-69. PubMed ID: 17390261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GABA dysfunction in the pathophysiology of tardive dyskinesia.
    Tamminga CA; Thaker GK; Chase TN
    Psychopharmacology Suppl; 1985; 2():122-7. PubMed ID: 2987903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The natural history of tardive dyskinesia.
    Gardos G; Cole JO; Haskell D; Marby D; Paine SS; Moore P
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):31S-37S. PubMed ID: 2906068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
    Alpert M; Friedhoff AJ; Diamond F
    Adv Neurol; 1983; 37():253-8. PubMed ID: 6134444
    [No Abstract]   [Full Text] [Related]  

  • 37. Tardive dyskinesia: a role for the endogenous opioid system.
    Sandyk R
    Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The current status of tardive dyskinesia.
    Sachdev PS
    Aust N Z J Psychiatry; 2000 Jun; 34(3):355-69. PubMed ID: 10881961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-induced movement disorders.
    Gershanik OS
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):369-76. PubMed ID: 8099509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P; Bédard PJ; Britton DR; Kebabian JW
    J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.